On a consolidated footing, Grasim's top-line has compounded at 14.5% over the past three fiscal years, scaling from ₹95,701 Crore in FY22 to ₹1,30,978 Crore in FY24, and crossing ₹1,34,500 Crore on a TTM basis. This headline expansion was largely powered by the pricing resilience and capacity expansion of UltraTech Cement, paired with rapid loan book growth at Aditya Birla Capital. Standalone revenue, however, tells a cyclical tale: after registering ₹26,840 Crore in FY23 on the back of historic commodity price highs, standalone sales softened to ₹25,800 Crore in FY24 as realization for caustic soda plummeted from peak rates of ₹70,000/ton to sub-₹35,000/ton.
Operating profitability has witnessed clear cyclical compression. Consolidated EBITDA margins declined from 18.2% in FY22 to 15.2% in FY24, while standalone EBITDA margins were squeezed harder, falling from 16.5% down to 11.8%. The margin contraction is dual-pronged: severe price realization drops across global VSF and domestic Chlor-Alkali segments, compounded by the upfront revenue drag of the Birla Opus launch, which incurs massive marketing outlays, plant depreciation, and dealer incentives before hitting utilization economies of scale.
The standalone balance sheet has fundamentally altered its character. Previously an underleveraged cash compounder with net cash or nominal debt, Grasim's standalone net debt expanded to ₹6,500 Crore by late FY24 to finance the ₹10,000 Crore paint capex and the ramp-up of Birla Pivot. Consolidated gross debt sits near ₹1,20,000 Crore, primarily reflecting Aditya Birla Capital's NBFC lending liabilities and UltraTech's capacity acquisitions. Free cash flow on a standalone basis turned sharply negative in FY24 at -₹4,200 Crore, reflecting the peak of its mega-capex program.
The principal red flag is the drag on returns on capital during this gestation phase. Standalone Return on Capital Employed (ROCE) has dipped into the mid-single digits (6-7%). Until Birla Opus plants achieve 50-60% capacity utilization, the business faces significant operating leverage headwinds and continued pricing retaliation from incumbents, which will depress standalone earnings until FY27.